Select Your Region
Global
Search results
Review the results we have found for you.
Use the filters to narrow down the results list and easily find the trial you look for.
Refine your search
Search
Hemophilia A
Location
Please note that the recruitment status of the study at your site may differ from the overall study status because some study sites may recruit earlier than others.
We found 5 results for 'HEMOPHILIA A'Use the filters to narrow down your search.
1 
Study StatusActive, not recruiting1 A study to look at how safe emicizumab treatment is and how well it works to prevent bleeds in children with haemophilia A (without factor 8 inhibitors) who started emicizumab in their first year of life
A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Subcutaneous Emicizumab in Participants From Birth to 12 Months of Age With Hemophilia A Without Inhibitors
- Hemophilia,
- Hemophilia A,
- Severe Hemophilia A
- NCT04431726, MO41787, 2020-001733-12,2023-505964-13-00
2 Study StatusActive, not recruiting2 A clinical trial to look at how safe emicizumab is in patients with mild or moderate hemophilia A, and how emicizumab affects bleeding in this patient population.
A Study to Evaluate the Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of Emicizumab in Participants With Mild or Moderate Hemophilia A Without FVIII Inhibitors
- Hemophilia,
- Hemophilia A
- NCT04158648, BO41423, 2023-506610-52-00
3 
Study StatusCompleted3 A Clinical Trial to Evaluate Prophylactic Emicizumab Versus no Prophylaxis in Hemophilia A Participants Without Inhibitors (HAVEN3)
A Clinical Trial to Evaluate Prophylactic Emicizumab Versus no Prophylaxis in Hemophilia A Participants Without Inhibitors
- Hemophilia,
- Hemophilia A
- NCT02847637, BH30071, 2016-000072-17, HAVEN3
4 Study StatusCompleted4 A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Prophylactic Emicizumab Versus no Prophylaxis in Hemophilia A Participants With Inhibitors (HAVEN1)
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Prophylactic Emicizumab Versus no Prophylaxis in Hemophilia A Participants With Inhibitors
- Hemophilia,
- Hemophilia A
- NCT02622321, BH29884, 2015-002866-21, HAVEN1
5 Study StatusCompleted5 A Study of Emicizumab Administered Subcutaneously (SC) in Pediatric Participants With Hemophilia A and Factor VIII (FVIII) Inhibitors (HAVEN2)
A Study of Emicizumab Administered Subcutaneously (SC) in Pediatric Participants With Hemophilia A and Factor VIII (FVIII) Inhibitors
- Hemophilia,
- Hemophilia A
- NCT02795767, BH29992, 2016-000073-21, HAVEN2